NCT06090318 2023-10-19Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossRain Oncology IncPhase 1/2 Withdrawn
NCT05429866 2023-03-08Immunological Variables Associated to ICI Toxicity in Cancer PatientsJules Bordet InstitutePhase 2 Unknown441 enrolled